This page is updated frequently with new Peptide-related patent applications.
|Biomarkers of osteoarthritis|
Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (oa) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including mcp1, il8, kc, mmp2, mmp3, apolipoprotein a1, and apolipoprotein e. Related methods for monitoring oa treatment efficacy, diagnostic reagents, and kits are also described..
The Curators Of The University Of Missouri
|Quantifying fr-alpha and gart proteins for optimal cancer therapy|
Improved methods are provided for treating cancer patients, particularly patients suffering from lung cancer. Methods are provided for identifying whether a lung tumor will be responsive to treatment with a therapeutic regimen that includes pemetrexed and optionally includes cisplatin.
Expression Pathology, Inc.
|Predictive biomarkers for detection of organ damage in autoimmune illnesses and other diseases|
The invention provides methods for identifying the presence of, or an increased risk of developing, organ damage in a subject having an autoimmune disease, for example, systemic lupus erythematosus (sle) or mixed connective tissue disease (mctd), or other disease in which the lungs and/or kidneys are involved. In one embodiment, a significantly increased combined igm reactivity against the peptides having the sequences of seq id nos: 4, 9, 12, and 15 in a sample obtained from a patient compared to a healthy control indicates lung damage or an increased risk of developing lung damage in the subject.
The Florida International University Board Of Trustees
|Methods for treating textiles using polypeptides having endoglucanase activity|
The present invention relates to isolated polypeptides having endoglucanase activity, catalytic domains, carbohydrate binding modules and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding modules. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding modules..
|Affinity tag nucleic acid and protein compositions, and processes for using same|
The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups..
Enzo Biochem, Inc.
A method for producing from host cells a heterologous polypeptide or protein comprising at least one cysteine residue in a reduced state. The method cultured the host cells in a culture medium comprising a reducing agent; and recovered the heterologous polypeptide or protein comprising at least one cysteine residue in a reduced state from the host cells or from the culture medium, where the host cells comprise a nucleic acid encoding the heterologous protein or polypeptide, and where the reducing agent is capable of permeating the plasma membrane of the host cells..
Thermo Fisher Scientific Baltics Uab
|Methods of dna constructs for high yield production of polypeptides|
The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.. .
|Compositions and methods for making selenocysteine containing polypeptides|
Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
|Useful halophilic, thermostable and ionic liquids tolerant cellulases|
The present invention provides for an isolated or recombinant polypeptide comprising an amino acid sequence having at least 70% identity with the amino acid sequence of a halorhabdus utahensis cellulase, such as hu-cbh1, wherein said amino acid sequence has a halophilic thermostable and/or thermophilic cellobiohydrolase (cbh) activity. In some embodiments, the polypeptide has a cbh activity that is resistant to up to about 20% of ionic liquids.
|Selection in fungi|
The present invention relates to methods for constructing a recombinant fungal host cell comprising one or more copies of a polynucleotide construct integrated in its genome, said method comprising transforming a fungal host cell with an integrative polynucleotide construct comprising a first polynucleotide encoding a selectable marker, wherein the first polynucleotide, a 5′ untranslated region thereof and/or a riboswitch operably linked therewith comprises a spliceosomal intron which has 5 nucleotides or less between its branch site and its acceptor site; and a second polynucleotide encoding a polypeptide of interest; as well as suitable polynucleotide constructs, resulting fungal host cells and methods of manufacture.. .
Methods and compositions for secretion of heterologous polypeptides
The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria.
Polypeptides having protease activity and polynucleotides encoding same
The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention further relates to the use of such polypeptides in detergent and/or in cleaning processes.
Variant lovd polypeptide
The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the lovd acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin.
The Regents Of The University Of California
Recombinantly engineered cells expressing chlorite dismutase and methods for using same in cell culture
The present disclosure relates to recombinantly engineered cells that contain a chlorite dismutase polypeptide and methods for culturing such cells in a culture medium containing chlorite in an amount sufficient to reduce the growth rate or kill contaminating microorganisms without killing the recombinantly engineered cells. Also provided are methods for the production of a fermentation product using the recombinantly engineered cells..
The Regents Of The University Of California
Polypeptides having peroxygenase activity and polynucleotides encoding same
The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Methods for reprogramming cells and uses thereof
An in vitro human cardiac multi potent or unipotent cell that has the ability to proliferate; may be maintained in standard cardiac stem cell media; can differentiate to a progenitor, precursor, or somatic cell; has the characteristics of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; does not exhibit uncontrolled growth, teratoma formation, or tumor formation in vivo; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; and is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; wherein the cell comprises at least one transiently expressed polypeptide or an expression vector.. .
Genesis Technologies Limited
Fermentation of fruit juices
A method of introducing yeast into a fruit juice such as grape must to be fermented is disclosed. The method comprises feeding dry yeast into a flowing stream of the fruit juice and delivering the flowing stream of fruit juice with the yeast in it to a mixer (10).
Rymco International Ag
Anti-cd123 antibodies and conjugates and derivatives thereof
The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to cd123 antigen (the α chain of the interleukine 3 receptor, or il-3rα). The present invention also relates to methods of using such cd123-binding molecules for diagnosing and treating diseases, such as b-cell malignancies..
Pdgf receptor beta binding polypeptides
The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human pdgfrβ) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides.
Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh
Isolated t cell receptors and methods of use therefor
Provided are isolated tcrs, tcr-like molecules, and portions thereof that bind to phosphopeptide-hla-a2 complexes. The isolated tcrs, tcr-like molecules, or portions are optionally soluble tcrs, tcr-like molecules, or portions.
University Of Virginia Patent Foundation
Murine anti-ny-eso-1 t cell receptors
The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
Modified fgf-21 polypeptides comprising an internal deletion and uses thereof
Modified fgf-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified fgf-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner..
Bristol-myers Squibb Company
Polypeptide and anti-tumor agent
Provided is a polypeptide comprising an r domain of crm197 and comprising one or more amino acid substitutions or deletions at positions selected from the group consisting of 391, 460, 466, 467, 468, 472, 507, and 520 of the r domain.. .
Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
A fusion protein for use as an immunogen enhancer for enhancing antigen-specific t cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (apc)-binding domain or a cd91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the apc-binding domain or the cd91 receptor-binding domain is located at the n-terminus of the fusion protein, and the antigen of the pathogen is located at the c-terminus of the protein transduction domain.
Thevax Genetics Vaccine Co., Ltd.
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.
Method of producing bivalirudin
The present disclosure provides a method of producing bivalirudin using a peptide fragment or peptide fragments on solid phase peptide synthesis that minimizes, or eliminates, the production of bivalirudin molecules having too few or too many glycine residues.. .
Peptides whose uptake by cells is controllable
A generic structure for the peptides of the present invention includes a-x-b-c, where c is a cargo moiety, the b portion includes basic amino acids, x is a cleavable linker sequence, and the a portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of x, the b-c portion is taken up, delivering the cargo to targeted cells.
The Regents Of The University Of California
Viral vector for the targeted transfer of genes in the brain and spinal cord
The invention relates to novel peptides, polypeptides or proteins which bind specifically to brain cells and/or to the spinal cord. The peptides, polypeptides, or proteins can be components of a viral capsid and can be used to lead a recombinant viral vector selectively to the brain and/or spinal cord after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there.
Saa-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
Isolated saa peptides, fusion proteins and compositions comprising such are provided as are domain-specific saa antibodies. Methods of treating sepsis and endotoxemia are also provided..
The Feinstein Institue For Medical Research
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a bet family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone n-terminal tail)..
Dana-farber Cancer Institute, Inc.
Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins
There is provided a compound of formula i, having the structure: wherein r1 to r5 have the meanings given in the description.. .
Nanyang Technological University